Clinical Trial Update: Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study [Phase 2]

View source ↗

Summary

Phase 2 trial (TRAMP) testing the combo of golimumab and apalutamide for metastatic castration-resistant prostate cancer is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Simponi (golimumab)

Snippet

Sponsor: University of Washington | Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING